Methylphenidate - Revision history

Maintenance script: parser-claude (pharmacist-claude hat): citation pass + content fills per Mark go 2026-05-26. Adds: history section (Panizzon 1944, Ciba launch, Schedule II 1971, MTA study, Cooper 2011 CV outcomes), Cortese 2018 NMA in intro, FDA warning refs (4), references/> infrastructure, FDA Ritalin label ref on PK, Ritalin IR indication clarification, MPH-TCA interaction revision, anecdote typo fix.

2026-05-27T01:10:09Z

parser-claude (pharmacist-claude hat): citation pass + content fills per Mark go 2026-05-26. Adds: history section (Panizzon 1944, Ciba launch, Schedule II 1971, MTA study, Cooper 2011 CV outcomes), Cortese 2018 NMA in intro, FDA warning refs (4), references/> infrastructure, FDA Ritalin label ref on PK, Ritalin IR indication clarification, MPH-TCA interaction revision, anecdote typo fix.

← Older revision		Revision as of 01:10, 27 May 2026
Line 14:		Line 14:
	\| pregnancy = Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion.		\| pregnancy = Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion.
	\| legal = Schedule II		\| legal = Schedule II
	\| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system psychostimulant and the most widely prescribed med for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor, distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need.		\| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system psychostimulant and the most widely prescribed med for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor, distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need. A 2018 systematic review and network meta-analysis by Cortese and colleagues identified methylphenidate as first-line pharmacotherapy for ADHD in children and adolescents (based on the balance of efficacy and tolerability), with amphetamines as first-line in adults.<ref name="cortese2018">Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2018;5(9):727–738.</ref>
	\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver, not by cytochrome P450 enzymes, to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated med interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.		\| history =
			Methylphenidate emerged from a chemistry program at the Swiss pharmaceutical company Ciba AG (later Ciba-Geigy, then Novartis) in the 1940s. Leandro Panizzon, a chemist at Ciba, synthesized the compound in 1944 while searching for a stimulant with a less abrupt and less euphoric profile than amphetamine. Panizzon and his colleagues observed the stimulant effect in animals and ultimately on themselves; the canonical anecdote, widely repeated in pharmacology histories and Ciba/Novartis corporate retrospectives, is that Panizzon's wife Marguerite ("Rita") used the compound as a mild stimulant before tennis matches, which inspired the trade name Ritalin.{{citation needed}}<!-- Candidate: Myers RE. Leandro Panizzon and the discovery of methylphenidate. Or: Ciba-Geigy / Novartis corporate history. The Rita-Panizzon attribution is widely repeated but a primary attribution source should be verified at publish. -->

			Ciba launched methylphenidate as Ritalin in Switzerland in 1954 and in the United States the following year, originally marketed for narcolepsy, chronic fatigue, mild depression, senile behavioral problems, and as an amphetamine-overdose antidote (this last use long since abandoned). Clinical application to childhood behavioral disorders developed gradually through the late 1950s and 1960s; the diagnosis then was "minimal brain dysfunction" or "hyperkinetic reaction of childhood," the precursors to the modern attention-deficit hyperactivity disorder formulation.{{citation needed}}<!-- Candidate: Healy D. The Creation of Psychopharmacology. Harvard University Press, 2002. Or Conrad P. The Discovery of Hyperkinesis: Notes on the Medicalization of Deviant Behavior. Social Problems. 1975;23(1):12–21. -->

			Methylphenidate was placed on Schedule II of the U.S. Controlled Substances Act in 1971, alongside amphetamine and cocaine, where it has remained.<ref name="csa-1971">U.S. Drug Enforcement Administration. Controlled Substances Act (21 U.S.C. §§ 801–971), Schedule II. 21 CFR 1308.12.</ref> The 1990s and 2000s saw a marked expansion of ADHD diagnosis and methylphenidate prescribing in the United States, accompanied by the development of extended-release formulations (Concerta osmotic-pump tablets approved 2000; Ritalin LA 2002; Metadate CD 2001; Daytrana transdermal patch 2006) that reduced the practical burden of multiple-times-daily dosing and supported broader adult use.

			The largest independent comparative-effectiveness data source on methylphenidate is the Multimodal Treatment of ADHD (MTA) study, a National Institute of Mental Health-funded randomized controlled trial published in 1999 that compared medication management (predominantly methylphenidate), behavioral therapy, the combination of both, and community standard care in 579 children aged 7–9 with ADHD. The medication and combined arms produced significantly greater improvement in ADHD symptoms than the behavioral or community arms at 14 months.<ref name="mta1999">MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry. 1999;56(12):1073–1086.</ref> Long-term follow-ups have moderated the short-term superiority finding, with diminishing between-group differences by 36 months and broadly comparable functional outcomes across arms by adulthood.{{citation needed}}<!-- Candidate: Swanson JM et al on MTA long-term follow-ups, multiple papers 2007–2019. Verify exact PMID at publish. -->

			Cardiovascular safety in long-term outpatient use was characterized by Cooper and colleagues in a large 2011 cohort study published in the New England Journal of Medicine: among 1,200,438 children and young adults receiving ADHD medications, no significant association with serious cardiovascular events was found compared with non-users, after adjustment for cardiovascular risk factors.<ref name="cooper2011">Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine. 2011;365(20):1896–1904.</ref> A companion JAMA study by Habel and colleagues reached similar conclusions in adults.<ref name="habel2011">Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673–2683.</ref> These analyses attenuated the post-2006 cardiac-safety concerns that had driven the peripheral vasculopathy and sudden-cardiac-death warnings, though the FDA warnings remain in place.
			\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver, not by cytochrome P450 enzymes, to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated med interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.<ref name="ritalin-label">U.S. Food and Drug Administration. Ritalin (methylphenidate hydrochloride) prescribing information. NDA 010187, Novartis Pharmaceuticals.</ref>
	\| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters, it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.		\| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters, it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.

Line 28:		Line 38:
	* Narcolepsy		* Narcolepsy
	* Off-label: treatment-resistant depression (augmentation, especially in geriatric or medically ill patients), fatigue in advanced illness (cancer, HIV, multiple sclerosis), excessive daytime sleepiness in shift-work disorder		* Off-label: treatment-resistant depression (augmentation, especially in geriatric or medically ill patients), fatigue in advanced illness (cancer, HIV, multiple sclerosis), excessive daytime sleepiness in shift-work disorder
	\| dosing = '''Ritalin IR (children ≥6 y~~, adults~~):''' Start 5 mg PO twice daily (before breakfast and lunch); titrate by 5–10 mg/week. Max 60 mg/day in 2–3 divided doses.		\| dosing = '''Ritalin IR (FDA-approved for children ≥6 y; adult use is common clinical practice but off-label for IR Ritalin specifically; several ER formulations carry adult ADHD indications):''' Start 5 mg PO twice daily (before breakfast and lunch); titrate by 5–10 mg/week. Max 60 mg/day in 2–3 divided doses.
	'''Ritalin LA / Metadate CD:''' 20 mg PO once daily AM; titrate by 10–20 mg weekly. Max 60 mg/day.		'''Ritalin LA / Metadate CD:''' 20 mg PO once daily AM; titrate by 10–20 mg weekly. Max 60 mg/day.
	'''Concerta (osmotic ER):''' Start 18 mg PO once daily AM. Titrate by 18 mg/week. Max 72 mg/day (adults); 54 mg/day (children).		'''Concerta (osmotic ER):''' Start 18 mg PO once daily AM. Titrate by 18 mg/week. Max 72 mg/day (adults); 54 mg/day (children).
Line 37:		Line 47:
	\| effects = ''Therapeutic:'' improved attention, reduced impulsivity and hyperactivity, increased wakefulness, mild mood elevation, mild appetite suppression. Generally described as "smoother" and less euphoric than amphetamines at equivalent doses.		\| effects = ''Therapeutic:'' improved attention, reduced impulsivity and hyperactivity, increased wakefulness, mild mood elevation, mild appetite suppression. Generally described as "smoother" and less euphoric than amphetamines at equivalent doses.
	''Common adverse:'' decreased appetite, insomnia (especially with late dosing), headache, abdominal pain, mild irritability, dry mouth, mild elevation of heart rate and blood pressure, weight loss.		''Common adverse:'' decreased appetite, insomnia (especially with late dosing), headache, abdominal pain, mild irritability, dry mouth, mild elevation of heart rate and blood pressure, weight loss.
	\| adverse = * '''Cardiovascular:''' tachycardia, mild–moderate hypertension; rare reports of sudden cardiac death in patients with structural heart disease (~~FDA warning~~)		\| adverse = * '''Cardiovascular:''' tachycardia, mild–moderate hypertension; rare reports of sudden cardiac death in patients with structural heart disease.<ref name="fda-mph-cv-2007">U.S. Food and Drug Administration. FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events. February 21, 2007.</ref><ref name="vetter2008">Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association. Circulation. 2008;117(18):2407–2423.</ref>
	* '''Psychiatric:''' anxiety, agitation, irritability, mood lability; rarely psychosis or mania (especially in patients with bipolar predisposition)		* '''Psychiatric:''' anxiety, agitation, irritability, mood lability; rarely psychosis or mania (especially in patients with bipolar predisposition)
	* '''Tics''', methylphenidate can unmask or worsen motor/vocal tics; comorbid Tourette syndrome is a traditional but increasingly contested relative contraindication		* '''Tics''', methylphenidate can unmask or worsen motor/vocal tics; comorbid Tourette syndrome is a traditional but increasingly contested relative contraindication
	* '''Dependence and misuse''', Schedule II; oral therapeutic use has lower abuse liability than amphetamines, but crushed/insufflated/IV misuse is significant		* '''Dependence and misuse''', Schedule II; oral therapeutic use has lower abuse liability than amphetamines, but crushed/insufflated/IV misuse is significant
	* '''Growth suppression''', modest reduction in height/weight velocity in chronically-treated children		* '''Growth suppression''', modest reduction in height/weight velocity in chronically-treated children
	* '''Priapism''', rare but documented; FDA warning, especially in adolescents		* '''Priapism''', rare but documented; FDA warning, especially in adolescents.<ref name="fda-mph-priapism-2013">U.S. Food and Drug Administration. FDA Drug Safety Communication: Safety review update of medical drugs used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults. December 17, 2013 (priapism class warning).</ref>
	* '''Peripheral vasculopathy''', Raynaud-like phenomenon, rare digital ischemia		* '''Peripheral vasculopathy''', Raynaud-like phenomenon, rare digital ischemia.<ref name="fda-mph-vasculopathy-2006">U.S. Food and Drug Administration. FDA Drug Safety Communication: peripheral vasculopathy including Raynaud phenomenon associated with stimulants used to treat ADHD. December 2006.</ref>
	* '''Lowered seizure threshold''', caution in epilepsy		* '''Lowered seizure threshold''', caution in epilepsy
	* '''Lassitude / "crash"''' on withdrawal, fatigue, dysphoria, rebound hyperactivity		* '''Lassitude / "crash"''' on withdrawal, fatigue, dysphoria, rebound hyperactivity
	* '''Stereotyped behaviors''', rare at therapeutic doses		* '''Stereotyped behaviors''', rare at therapeutic doses
	* '''Skin reactions''', chemical leukoderma (permanent depigmentation) at Daytrana patch application sites		* '''Skin reactions''', chemical leukoderma (permanent depigmentation) at Daytrana patch application sites.<ref name="fda-daytrana-leukoderma-2015">U.S. Food and Drug Administration. FDA Drug Safety Communication: Permanent skin color loss (chemical leukoderma) reported with use of Daytrana patch (methylphenidate transdermal system). June 24, 2015.</ref>
	\| interactions = * '''MAOIs''' (phenelzine, tranylcypromine, selegiline, linezolid), hypertensive crisis risk; contraindicated		\| interactions = * '''MAOIs''' (phenelzine, tranylcypromine, selegiline, linezolid), hypertensive crisis risk; contraindicated
	* '''Tricyclic antidepressants''', ~~methylphenidate may elevate~~ TCA ~~plasma~~ levels; ~~additive cardiovascular effects~~		* '''Tricyclic antidepressants''', additive sympathomimetic cardiovascular effects (tachycardia, hypertension). Older case reports suggested possible PK interaction elevating TCA levels; modern reviews do not support a clinically significant PK interaction as methylphenidate does not appreciably inhibit CYP2D6.
	* '''Warfarin / coumarins''', methylphenidate may elevate INR		* '''Warfarin / coumarins''', methylphenidate may elevate INR
	* '''Phenytoin, phenobarbital, primidone''', methylphenidate may elevate anticonvulsant levels		* '''Phenytoin, phenobarbital, primidone''', methylphenidate may elevate anticonvulsant levels
Line 79:		Line 89:
	\| anecdotes =		\| anecdotes =
	<anecdote slug="2026-05-14" perspective="provider" author="MDElliottMD">		<anecdote slug="2026-05-14" perspective="provider" author="MDElliottMD">
	Rumor has it that can be more ~~effect~~ during luteal phase of ~~menstruation~~. Anyone have experience?		Rumor has it that it can be more effective during the luteal phase of the menstrual cycle. Anyone have experience?
	</anecdote>		</anecdote>
	\| seealso = [[Mixed amphetamine salts]], [[Dextroamphetamine]], [[Dexmethylphenidate]], [[Lisdexamfetamine]], [[Modafinil]], [[Atomoxetine]], [[Viloxazine]]		\| seealso = [[Mixed amphetamine salts]], [[Dextroamphetamine]], [[Dexmethylphenidate]], [[Lisdexamfetamine]], [[Modafinil]], [[Atomoxetine]], [[Viloxazine]]
	\| references =		\| references = <references/>
	}}		}}

	[[Category:Psychostimulants]]		[[Category:Psychostimulants]]
	[[Category:Methylphenidates (Phenidates)]]		[[Category:Methylphenidates (Phenidates)]]

MDElliottMD: parser-claude: targeted corrections, 7 fix(es) (stale FDA Cat C; house-rule banned terms)

2026-05-23T20:39:22Z

parser-claude: targeted corrections, 7 fix(es) (stale FDA Cat C; house-rule banned terms)

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:09Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

MDElliottMD: Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name)

2026-05-19T01:37:42Z

Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name)

← Older revision		Revision as of 01:37, 19 May 2026
Line 60:		Line 60:
	Notably, '''few CYP-mediated interactions''' because methylphenidate is metabolized by CES1, not P450s — a clinical advantage over amphetamine when polypharmacy is a concern.		Notably, '''few CYP-mediated interactions''' because methylphenidate is metabolized by CES1, not P450s — a clinical advantage over amphetamine when polypharmacy is a concern.
	<pharmaInteractions/>		<pharmaInteractions/>
	\| pregnancy_details = Category C. Crosses the placenta. Less reproductive data than amphetamine; available evidence does not show a clear pattern of major teratogenicity, but cohort studies suggest small increases in cardiac malformations and other anomalies — interpretation complicated by confounding by ~~indication~~. Third-trimester exposure can produce transient neonatal withdrawal (irritability, feeding difficulty). Generally a risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in small amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.		\| pregnancy_details = Category C. Crosses the placenta. Less reproductive data than amphetamine; available evidence does not show a clear pattern of major teratogenicity, but cohort studies suggest small increases in cardiac malformations and other anomalies — interpretation complicated by confounding by problem. Third-trimester exposure can produce transient neonatal withdrawal (irritability, feeding difficulty). Generally a risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in small amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.
	\| monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use		\| monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use
	* Consider ECG if cardiac risk factors are present		* Consider ECG if cardiac risk factors are present

MDElliottMD: Recategorize: Stimulants -> Psychostimulants

2026-05-17T10:50:53Z

Recategorize: Stimulants -> Psychostimulants

← Older revision		Revision as of 10:50, 17 May 2026
Line 85:		Line 85:
	}}		}}

	[[Category:~~Stimulants~~]]		[[Category:Psychostimulants]]
	[[Category:Methylphenidates (Phenidates)]]		[[Category:Methylphenidates (Phenidates)]]

MDElliottMD: Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

2026-05-17T10:45:08Z

Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants

← Older revision		Revision as of 10:45, 17 May 2026
Line 85:		Line 85:
	}}		}}

	[[Category:Stimulants ~~& Wake-Promoting Agents~~]]		[[Category:Stimulants]]
	[[Category:Methylphenidates (Phenidates)]]		[[Category:Methylphenidates (Phenidates)]]

Maintenance script: Terminology: medicine → med (shorter form per user preference)

2026-05-16T02:42:46Z

Terminology: medicine → med (shorter form per user preference)

Maintenance script: Terminology sweep (site-wide): drug/medication → medicine

2026-05-16T02:30:55Z

Terminology sweep (site-wide): drug/medication → medicine

← Older revision		Revision as of 02:30, 16 May 2026
Line 15:		Line 15:
	\| legal = Schedule II		\| legal = Schedule II
	\| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system stimulant and the most widely prescribed medicine for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor — distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need.		\| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system stimulant and the most widely prescribed medicine for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor — distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need.
	\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver — not by cytochrome P450 enzymes — to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated ~~drug~~ interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.		\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver — not by cytochrome P450 enzymes — to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated medicine interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.
	\| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters — it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.		\| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters — it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.

Line 64:		Line 64:
	* Consider ECG if cardiac risk factors are present		* Consider ECG if cardiac risk factors are present
	* At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence		* At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence
	* Periodically reassess continued need; consider ~~drug~~ holidays in children to assess ongoing benefit and minimize growth-velocity effects		* Periodically reassess continued need; consider medicine holidays in children to assess ongoing benefit and minimize growth-velocity effects
	* Sleep quality and timing of last dose		* Sleep quality and timing of last dose
	\| counseling = * Take in the morning; avoid afternoon dosing to minimize insomnia.		\| counseling = * Take in the morning; avoid afternoon dosing to minimize insomnia.

MDElliottMD: Proposed anecdote (provider)

2026-05-14T18:50:38Z

Proposed anecdote (provider)

← Older revision		Revision as of 18:50, 14 May 2026
Line 78:		Line 78:
	* If discontinuing after long use, expect a few days of fatigue and possible dysphoria.		* If discontinuing after long use, expect a few days of fatigue and possible dysphoria.
	\| anecdotes =		\| anecdotes =
			<anecdote slug="2026-05-14" perspective="provider" author="MDElliottMD">
			Rumor has it that can be more effect during luteal phase of menstruation. Anyone have experience?
			</anecdote>
	\| seealso = [[Mixed amphetamine salts]], [[Dextroamphetamine]], [[Dexmethylphenidate]], [[Lisdexamfetamine]], [[Modafinil]], [[Atomoxetine]], [[Viloxazine]]		\| seealso = [[Mixed amphetamine salts]], [[Dextroamphetamine]], [[Dexmethylphenidate]], [[Lisdexamfetamine]], [[Modafinil]], [[Atomoxetine]], [[Viloxazine]]
	\| references =		\| references =

MDElliottMD: Removed anecdote "2026-05-14"

2026-05-14T18:50:20Z

Removed anecdote "2026-05-14"

← Older revision		Revision as of 18:50, 14 May 2026
Line 78:		Line 78:
	* If discontinuing after long use, expect a few days of fatigue and possible dysphoria.		* If discontinuing after long use, expect a few days of fatigue and possible dysphoria.
	\| anecdotes =		\| anecdotes =
	~~<anecdote slug="2026-05-14" perspective="personal" author="MDElliottMD">~~
	~~Rumor has it that can be more effect during luteal phase of menstruation.~~
	~~</anecdote>~~
	\| seealso = [[Mixed amphetamine salts]], [[Dextroamphetamine]], [[Dexmethylphenidate]], [[Lisdexamfetamine]], [[Modafinil]], [[Atomoxetine]], [[Viloxazine]]		\| seealso = [[Mixed amphetamine salts]], [[Dextroamphetamine]], [[Dexmethylphenidate]], [[Lisdexamfetamine]], [[Modafinil]], [[Atomoxetine]], [[Viloxazine]]
	\| references =		\| references =

← Older revision		Revision as of 20:39, 23 May 2026
Line 3:		Line 3:
	\| brand = Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR		\| brand = Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR
	\| structure = Methylphenidate.svg		\| structure = Methylphenidate.svg
	\| classes = Psychostimulant~~, CNS stimulant~~, NDRI		\| classes = Psychostimulant, NDRI
	\| mechanism = Norepinephrine–dopamine reuptake inhibition (DAT, NET)		\| mechanism = Norepinephrine–dopamine reuptake inhibition (DAT, NET)
	\| uses = ADHD, narcolepsy		\| uses = ADHD, narcolepsy
Line 12:		Line 12:
	\| halflife = 2–3 h (parent compound)		\| halflife = 2–3 h (parent compound)
	\| bioavailability = ~30% (high first-pass)		\| bioavailability = ~30% (high first-pass)
	\| pregnancy = ~~Category C~~		\| pregnancy = Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion.
	\| legal = Schedule II		\| legal = Schedule II
	\| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system ~~stimulant~~ and the most widely prescribed med for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor, distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need.		\| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system psychostimulant and the most widely prescribed med for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor, distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need.
	\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver, not by cytochrome P450 enzymes, to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated med interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.		\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver, not by cytochrome P450 enzymes, to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated med interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.
	\| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters, it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.		\| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters, it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.
Line 54:		Line 54:
	* '''Antihypertensives''', methylphenidate's pressor effect may partially antagonize		* '''Antihypertensives''', methylphenidate's pressor effect may partially antagonize
	* '''Other sympathomimetics''' (pseudoephedrine, phenylephrine, decongestants), additive cardiovascular effects		* '''Other sympathomimetics''' (pseudoephedrine, phenylephrine, decongestants), additive cardiovascular effects
	* '''~~Antipsychotics~~''', pharmacologic antagonism (each may partially block the other's effects)		* '''Neuroleptics''', pharmacologic antagonism (each may partially block the other's effects)
	* '''Alcohol''', may mask intoxication; may release more d-methylphenidate from racemic preparations via stereoselective metabolism		* '''Alcohol''', may mask intoxication; may release more d-methylphenidate from racemic preparations via stereoselective metabolism
	* '''Caffeine''', additive ~~stimulant~~ and anxiogenic effects		* '''Caffeine''', additive psychostimulant and anxiogenic effects

	Notably, '''few CYP-mediated interactions''' because methylphenidate is metabolized by CES1, not P450s, a clinical advantage over amphetamine when polypharmacy is a concern.		Notably, '''few CYP-mediated interactions''' because methylphenidate is metabolized by CES1, not P450s, a clinical advantage over amphetamine when polypharmacy is a concern.
	<pharmaInteractions/>		<pharmaInteractions/>
	\| pregnancy_details = ~~Category C.~~ Crosses the placenta. Less reproductive data than amphetamine; available evidence does not show a clear pattern of major teratogenicity, but cohort studies suggest small increases in cardiac malformations and other anomalies, interpretation complicated by confounding by problem. Third-trimester exposure can produce transient neonatal withdrawal (irritability, feeding difficulty). Generally a risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in small amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.		\| pregnancy_details = Crosses the placenta. Less reproductive data than amphetamine; available evidence does not show a clear pattern of major teratogenicity, but cohort studies suggest small increases in cardiac malformations and other anomalies, interpretation complicated by confounding by problem. Third-trimester exposure can produce transient neonatal withdrawal (irritability, feeding difficulty). Generally a risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in small amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.
	\| monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use		\| monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use
	* Consider ECG if cardiac risk factors are present		* Consider ECG if cardiac risk factors are present
Line 71:		Line 71:
	* Eat regular meals despite appetite suppression; weigh periodically.		* Eat regular meals despite appetite suppression; weigh periodically.
	* Stay well-hydrated.		* Stay well-hydrated.
	* Do not combine with significant alcohol or other ~~stimulants~~.		* Do not combine with significant alcohol or other psychostimulants.
	* Do not share or sell, Schedule II controlled substance; serious legal and clinical consequences.		* Do not share or sell, Schedule II controlled substance; serious legal and clinical consequences.
	* Report chest pain, palpitations, severe agitation, hallucinations, prolonged erection, or new/worsening tics.		* Report chest pain, palpitations, severe agitation, hallucinations, prolonged erection, or new/worsening tics.

← Older revision		Revision as of 03:16, 19 May 2026
Line 14:		Line 14:
	\| pregnancy = Category C		\| pregnancy = Category C
	\| legal = Schedule II		\| legal = Schedule II
	\| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system stimulant and the most widely prescribed med for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor — distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need.		\| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system stimulant and the most widely prescribed med for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor, distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need.
	\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver — not by cytochrome P450 enzymes — to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated med interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.		\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver, not by cytochrome P450 enzymes, to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated med interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.
	\| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters — it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.		\| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters, it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.

	Key effects:		Key effects:
Line 39:		Line 39:
	\| adverse = * '''Cardiovascular:''' tachycardia, mild–moderate hypertension; rare reports of sudden cardiac death in patients with structural heart disease (FDA warning)		\| adverse = * '''Cardiovascular:''' tachycardia, mild–moderate hypertension; rare reports of sudden cardiac death in patients with structural heart disease (FDA warning)
	* '''Psychiatric:''' anxiety, agitation, irritability, mood lability; rarely psychosis or mania (especially in patients with bipolar predisposition)		* '''Psychiatric:''' anxiety, agitation, irritability, mood lability; rarely psychosis or mania (especially in patients with bipolar predisposition)
	* '''Tics''' — methylphenidate can unmask or worsen motor/vocal tics; comorbid Tourette syndrome is a traditional but increasingly contested relative contraindication		* '''Tics''', methylphenidate can unmask or worsen motor/vocal tics; comorbid Tourette syndrome is a traditional but increasingly contested relative contraindication
	* '''Dependence and misuse''' — Schedule II; oral therapeutic use has lower abuse liability than amphetamines, but crushed/insufflated/IV misuse is significant		* '''Dependence and misuse''', Schedule II; oral therapeutic use has lower abuse liability than amphetamines, but crushed/insufflated/IV misuse is significant
	* '''Growth suppression''' — modest reduction in height/weight velocity in chronically-treated children		* '''Growth suppression''', modest reduction in height/weight velocity in chronically-treated children
	* '''Priapism''' — rare but documented; FDA warning, especially in adolescents		* '''Priapism''', rare but documented; FDA warning, especially in adolescents
	* '''Peripheral vasculopathy''' — Raynaud-like phenomenon, rare digital ischemia		* '''Peripheral vasculopathy''', Raynaud-like phenomenon, rare digital ischemia
	* '''Lowered seizure threshold''' — caution in epilepsy		* '''Lowered seizure threshold''', caution in epilepsy
	* '''Lassitude / "crash"''' on withdrawal — fatigue, dysphoria, rebound hyperactivity		* '''Lassitude / "crash"''' on withdrawal, fatigue, dysphoria, rebound hyperactivity
	* '''Stereotyped behaviors''' — rare at therapeutic doses		* '''Stereotyped behaviors''', rare at therapeutic doses
	* '''Skin reactions''' — chemical leukoderma (permanent depigmentation) at Daytrana patch application sites		* '''Skin reactions''', chemical leukoderma (permanent depigmentation) at Daytrana patch application sites
	\| interactions = * '''MAOIs''' (phenelzine, tranylcypromine, selegiline, linezolid) — hypertensive crisis risk; contraindicated		\| interactions = * '''MAOIs''' (phenelzine, tranylcypromine, selegiline, linezolid), hypertensive crisis risk; contraindicated
	* '''Tricyclic antidepressants''' — methylphenidate may elevate TCA plasma levels; additive cardiovascular effects		* '''Tricyclic antidepressants''', methylphenidate may elevate TCA plasma levels; additive cardiovascular effects
	* '''Warfarin / coumarins''' — methylphenidate may elevate INR		* '''Warfarin / coumarins''', methylphenidate may elevate INR
	* '''Phenytoin, phenobarbital, primidone''' — methylphenidate may elevate anticonvulsant levels		* '''Phenytoin, phenobarbital, primidone''', methylphenidate may elevate anticonvulsant levels
	* '''Antihypertensives''' — methylphenidate's pressor effect may partially antagonize		* '''Antihypertensives''', methylphenidate's pressor effect may partially antagonize
	* '''Other sympathomimetics''' (pseudoephedrine, phenylephrine, decongestants) — additive cardiovascular effects		* '''Other sympathomimetics''' (pseudoephedrine, phenylephrine, decongestants), additive cardiovascular effects
	* '''Antipsychotics''' — pharmacologic antagonism (each may partially block the other's effects)		* '''Antipsychotics''', pharmacologic antagonism (each may partially block the other's effects)
	* '''Alcohol''' — may mask intoxication; may release more d-methylphenidate from racemic preparations via stereoselective metabolism		* '''Alcohol''', may mask intoxication; may release more d-methylphenidate from racemic preparations via stereoselective metabolism
	* '''Caffeine''' — additive stimulant and anxiogenic effects		* '''Caffeine''', additive stimulant and anxiogenic effects

	Notably, '''few CYP-mediated interactions''' because methylphenidate is metabolized by CES1, not P450s — a clinical advantage over amphetamine when polypharmacy is a concern.		Notably, '''few CYP-mediated interactions''' because methylphenidate is metabolized by CES1, not P450s, a clinical advantage over amphetamine when polypharmacy is a concern.
	<pharmaInteractions/>		<pharmaInteractions/>
	\| pregnancy_details = Category C. Crosses the placenta. Less reproductive data than amphetamine; available evidence does not show a clear pattern of major teratogenicity, but cohort studies suggest small increases in cardiac malformations and other anomalies — interpretation complicated by confounding by problem. Third-trimester exposure can produce transient neonatal withdrawal (irritability, feeding difficulty). Generally a risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in small amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.		\| pregnancy_details = Category C. Crosses the placenta. Less reproductive data than amphetamine; available evidence does not show a clear pattern of major teratogenicity, but cohort studies suggest small increases in cardiac malformations and other anomalies, interpretation complicated by confounding by problem. Third-trimester exposure can produce transient neonatal withdrawal (irritability, feeding difficulty). Generally a risk-benefit decision; many patients defer ADHD treatment during pregnancy. Excreted in breast milk in small amounts; breastfeeding generally compatible at therapeutic doses with infant monitoring.
	\| monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use		\| monitoring = * Baseline: cardiovascular history (including family history of sudden cardiac death), blood pressure, heart rate, weight/height, mental health history, history of tics or substance use
	* Consider ECG if cardiac risk factors are present		* Consider ECG if cardiac risk factors are present
Line 68:		Line 68:
	\| counseling = * Take in the morning; avoid afternoon dosing to minimize insomnia.		\| counseling = * Take in the morning; avoid afternoon dosing to minimize insomnia.
	* '''Do not crush, chew, or split extended-release tablets/capsules.'''		* '''Do not crush, chew, or split extended-release tablets/capsules.'''
	* '''Concerta:''' the osmotic tablet shell will appear intact in stool — this is normal and does not mean the med wasn't absorbed.		* '''Concerta:''' the osmotic tablet shell will appear intact in stool, this is normal and does not mean the med wasn't absorbed.
	* Eat regular meals despite appetite suppression; weigh periodically.		* Eat regular meals despite appetite suppression; weigh periodically.
	* Stay well-hydrated.		* Stay well-hydrated.
	* Do not combine with significant alcohol or other stimulants.		* Do not combine with significant alcohol or other stimulants.
	* Do not share or sell — Schedule II controlled substance; serious legal and clinical consequences.		* Do not share or sell, Schedule II controlled substance; serious legal and clinical consequences.
	* Report chest pain, palpitations, severe agitation, hallucinations, prolonged erection, or new/worsening tics.		* Report chest pain, palpitations, severe agitation, hallucinations, prolonged erection, or new/worsening tics.
	* Skin patches: rotate site daily to avoid persistent depigmentation; remove after 9 hours.		* Skin patches: rotate site daily to avoid persistent depigmentation; remove after 9 hours.
	* Plan for the "crash" when the dose wears off — particularly with IR formulations late afternoon.		* Plan for the "crash" when the dose wears off, particularly with IR formulations late afternoon.
	* If discontinuing after long use, expect a few days of fatigue and possible dysphoria.		* If discontinuing after long use, expect a few days of fatigue and possible dysphoria.
	\| anecdotes =		\| anecdotes =

← Older revision		Revision as of 02:42, 16 May 2026
Line 14:		Line 14:
	\| pregnancy = Category C		\| pregnancy = Category C
	\| legal = Schedule II		\| legal = Schedule II
	\| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system stimulant and the most widely prescribed ~~medicine~~ for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor — distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need.		\| intro = '''Methylphenidate''' is a piperidine-derivative central nervous system stimulant and the most widely prescribed med for attention-deficit hyperactivity disorder. First synthesized by Leandro Panizzon at Ciba in 1944 (and reportedly named "Ritalin" after his wife Rita, who used it), it has been clinically available since the mid-1950s. Mechanistically, methylphenidate is a pure norepinephrine–dopamine '''reuptake''' inhibitor — distinct from the amphetamines, which primarily ''release'' monoamines via reverse transport. This pharmacologic difference contributes to a somewhat smoother subjective profile and slightly lower abuse liability per milligram, though methylphenidate remains a Schedule II controlled substance with meaningful misuse potential. Multiple formulations exist (immediate-release, several extended-release oral preparations, a transdermal patch, and a chewable/liquid), allowing duration-of-action to be matched to clinical need.
	\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver — not by cytochrome P450 enzymes — to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated ~~medicine~~ interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.		\| pharmacokinetics = '''Absorption:''' Rapid oral absorption; peak plasma levels in 1–2 hours for IR. Bioavailability is only ~30% due to extensive first-pass metabolism. Food modestly delays but does not significantly reduce absorption. The transdermal patch (Daytrana) bypasses first-pass and produces somewhat higher and steadier serum levels per dose. '''Distribution:''' Volume of distribution ~13 L/kg; plasma protein binding ~15%. Crosses the blood–brain barrier. '''Metabolism:''' Primarily metabolized by '''carboxylesterase 1 (CES1)''' in the liver — not by cytochrome P450 enzymes — to ritalinic acid, which is pharmacologically inactive. This metabolic route makes methylphenidate relatively free of CYP-mediated med interactions, distinguishing it from amphetamines. '''Stereochemistry:''' Methylphenidate has two stereocenters; the d-threo enantiomer carries essentially all pharmacologic activity. Dexmethylphenidate ([[Focalin]]) is the isolated d-threo enantiomer and is roughly twice as potent per milligram. '''Elimination:''' ~90% renally excreted as ritalinic acid; ~1% unchanged. Half-life of the parent compound is 2–3 hours, hence the need for extended-release formulations or multi-dose-daily schedules for sustained effect.
	\| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters — it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.		\| pharmacodynamics = Methylphenidate binds to and competitively inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking reuptake of these monoamines from the synaptic cleft. Unlike amphetamines, methylphenidate is '''not a substrate''' for the transporters — it doesn't enter the presynaptic terminal, doesn't displace dopamine from vesicles, and doesn't induce reverse transport. The result is increased extracellular dopamine and norepinephrine without the additional vesicular release amphetamines produce.

Line 64:		Line 64:
	* Consider ECG if cardiac risk factors are present		* Consider ECG if cardiac risk factors are present
	* At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence		* At each visit: blood pressure, heart rate, weight (and height in children), efficacy, side effects, signs of misuse/diversion, tic emergence
	* Periodically reassess continued need; consider ~~medicine~~ holidays in children to assess ongoing benefit and minimize growth-velocity effects		* Periodically reassess continued need; consider med holidays in children to assess ongoing benefit and minimize growth-velocity effects
	* Sleep quality and timing of last dose		* Sleep quality and timing of last dose
	\| counseling = * Take in the morning; avoid afternoon dosing to minimize insomnia.		\| counseling = * Take in the morning; avoid afternoon dosing to minimize insomnia.
	* '''Do not crush, chew, or split extended-release tablets/capsules.'''		* '''Do not crush, chew, or split extended-release tablets/capsules.'''
	* '''Concerta:''' the osmotic tablet shell will appear intact in stool — this is normal and does not mean the ~~medicine~~ wasn't absorbed.		* '''Concerta:''' the osmotic tablet shell will appear intact in stool — this is normal and does not mean the med wasn't absorbed.
	* Eat regular meals despite appetite suppression; weigh periodically.		* Eat regular meals despite appetite suppression; weigh periodically.
	* Stay well-hydrated.		* Stay well-hydrated.